For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

As researchers and governments consider the therapeutic uses of psychedelics, Scott Marshall stands ready to supply them.

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

Forge consensus on a modern regulatory framework. The Trump administration could encourage the development of a ...

Starting today, people with Parkinson's disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

RFK Jr. plans to investigate SSRI and antidepressant use, particularly among children and teens, as part of the “Make America ...

G&A expenses were $15.3 million for the year ended December 31, 2024, compared to $11.4 million for the full year 2023. The increase was primarily due to higher professional fees, which has been ...